Protocol Ledger

NCT04419649 · Phase II · RECRUITING

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Interventional Phase II clinical trial protocol NCT04419649 sponsored by Takeda in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-19 Enrollment: 210 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04419649
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)210 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04419649
Protocol FieldVerified Registry Value
NCT IdentifierNCT04419649
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment210 participants (ESTIMATED)
Registered Start Date2020-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04419649
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI